CGTBiologicstaleBeijing BiotechPhase 2
CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))
Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2
#CLDN182#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING